Skip to content
OVERVIEW
Veracyte is a leading genomic diagnostics company that is fundamentally improving patient care by resolving diagnostic uncertainty with evidence that is trustworthy and actionable. The company’s products uniquely combine genomic technology, clinical science and machine learning to provide answers that give physicians and patients a clear path forward without risky, costly surgery that is often unnecessary.
Since its founding in 2008, Veracyte has commercialized three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis and collectively target a $2 billion market opportunity. Veracyte is based in South San Francisco, California. Veracyte’s common stock is listed on The NASDAQ Global Market under the symbol VCYT.

OVERVIEW

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Veracyte, Inc. to Host Conference Call and Webcast to Discuss Third Quarter 2014 Financial Results on November 13, 2014
SOUTH SAN FRANCISCO, Calif. , Nov. 6, 2014 /PRNewswire/ -- Veracyte, Inc. (Nasdaq: VCYT) announced today that its third quarter 2014 financial results will be released after close of market on Thursday, November 13, 2014 .  Following the announcement, Veracyte's management will host a live
View HTML
Toggle Summary Veracyte, Inc. to Host Conference Call and Webcast to Discuss Second Quarter 2014 Financial Results on August 13, 2014
SOUTH SAN FRANCISCO, Calif. , Aug. 6, 2014 /PRNewswire/ --  Veracyte, Inc. (Nasdaq: VCYT) announced today that its second quarter 2014 financial results will be released after close of market on Wednesday, August 13 , 2014.  Following the announcement, Veracyte's management will host a live
View HTML

Events

Date Event Details
Summary Toggle Jul 23, 2018 1:30 PM PDT
Veracyte Second Quarter 2018 Financial Results Webcast
Summary Toggle Jun 13, 2018 12:40 PM CDT
William Blair 2018 Growth Stock Conference

Speaker

Bonnie H. Anderson
Chairman of the Board and Chief Executive Officer

Presentations

Title Documents

Veracyte Corporate Presentation, June 2018